Published June 2, 2026 Updated June 16, 2026 8 min read

# A plain-English glossary of APOE4 terms

## The short version

This page is a decoder, not a protocol. APOE4 is a risk allele, not a deterministic mutation, and the words around it mix genes, probabilities, biomarkers, and treatment risks. Look up the term, then follow the linked review if you need to decide something.

By the OutliveAPOE4 editorial team. [How we research & source](/methodology).

Reading about APOE4 means wading through vocabulary borrowed from genetics, neurology, and cardiology all at once. This page is the cheat sheet. Keep it open while you read. The definitions are deliberately plain, with links to the deeper dives where they exist, and many end with why the term matters for you as a carrier.

## The genetics words

**APOE** is the gene, and the protein it makes, apolipoprotein E. Its day job is moving cholesterol and fats around the body and brain. The version you inherit is the whole reason this site exists.

**Allele** is one version of a gene. APOE comes in three common alleles: **ε2, ε3, and ε4** (often written 2, 3, 4).

**ε2 / ε3 / ε4** are those three versions. ε2 is rare and relatively protective, ε3 is the common neutral reference, and ε4 raises risk.

**Genotype** is your specific pair of alleles, one inherited from each parent, such as 3/4 or 4/4. This pair is what determines your risk, so it is the number to actually know. See [the genotypes explained](/topics/apoe4-genotypes-explained).

**Carrier** is shorthand for someone with at least one ε4 allele.

**Homozygous / heterozygous** describe the pair. Two copies of the same allele (for example ε4/ε4) is homozygous. Two different ones (for example ε3/ε4) is heterozygous. Why it matters: an ε4/ε4 homozygote carries higher risk than an ε3/ε4 heterozygote, so this distinction changes how your numbers read.

**SNP (single-nucleotide polymorphism)** is a single-letter spot in your DNA that varies from person to person. Your APOE type is set by just two of them, **rs429358** and **rs7412**. Why it matters: if you are reading a raw DNA file yourself, these are the exact two rows you need. See [how to read them in your raw data](/topics/find-your-apoe-status-23andme).

**Penetrance** is the fraction of people carrying a variant who actually develop the condition tied to it. APOE4 has **low-to-moderate penetrance**: only a subset of carriers ever develop Alzheimer’s, which is why it is called a risk factor and not a deterministic mutation. Two copies push penetrance higher (the Fortea 2024 study found ε4/ε4 behaves almost like a distinct genetic form of the disease). Why it matters: this single word is the difference between “raised odds” and “destiny,” and APOE4 is firmly the former.

**Sporadic vs. familial Alzheimer’s** are two different diseases that share a name. The **sporadic** (late-onset) form, the one APOE4 influences, makes up the vast majority of cases and has no single causative gene. **Familial** (autosomal-dominant, early-onset) Alzheimer’s is rare (under about 1 to 5% of cases), is caused by mutations in **APP, PSEN1, or PSEN2**, and is highly penetrant. Why it matters: APOE4 is a different biological story from the familial mutations, so do not read those scarier inevitability statistics as if they were about you.

## The risk words

**Relative risk** is how much a factor changes your odds *compared with* a reference group. It sounds dramatic (“twice the risk”) and on its own tells you nothing about your actual chance.

**Absolute risk** is your *actual* probability over a stated time horizon, such as “by age 85.” This is the number that matters. Why it matters: headlines quote relative risk because it sounds bigger; always ask for the absolute number before you panic. See [what the numbers mean](/topics/apoe4-and-alzheimers-risk).

**Modifiable risk factor** is an influence on risk you can actually change, such as blood pressure, activity, or sleep, as opposed to fixed ones like your genotype. Why it matters: these are where all your leverage lives.

## The brain words

**Amyloid-beta (Aβ)** is a protein fragment that clumps into **plaques** between neurons, one of the two hallmarks of Alzheimer’s. Why it matters: APOE4 is linked to clearing amyloid less efficiently, which is one of the main reasons the gene raises risk.

**Tau** is a protein that, in disease, twists into **tangles** (neurofibrillary tangles, sometimes shortened to NFTs) inside neurons, the second classic Alzheimer’s hallmark. Tau tracks more closely with actual symptoms than amyloid does. That is why **p-tau217**, a blood marker of tau pathology, has become such a useful early signal: it tells Alzheimer’s apart from other causes with roughly 90%-plus accuracy in recent studies. See [blood-based biomarkers](/topics/blood-based-biomarkers-alzheimers).

**Neuroinflammation** is the brain’s own immune response. Helpful in short bursts, but when it becomes chronic it may speed up damage.

**Blood-brain barrier** is the selective border that protects brain tissue from whatever is circulating in the bloodstream. Why it matters: APOE4 is linked to its breakdown, one more channel through which the gene acts. See [how APOE4 affects the brain](/topics/how-apoe4-affects-the-brain).

**Glymphatic system** is the brain’s waste-clearance plumbing, most active during deep sleep. Why it matters: it is a big part of why [sleep matters](/topics/sleep-and-apoe4) so much for carriers.

**Cognitive reserve** is the brain’s resilience, built up over a lifetime from education and mental and social engagement, that can buffer against pathology. Why it matters: it is one of the things you can keep building at any age. See [social connection and cognitive reserve](/topics/social-connection-and-cognitive-reserve).

**BDNF (brain-derived neurotrophic factor)** is a protein that supports the growth and upkeep of neurons. Why it matters: [exercise](/topics/exercise-and-apoe4) boosts it, which is part of how movement protects the brain.

**MCI (mild cognitive impairment)** is measurable decline beyond normal aging that does not yet derail daily life. Why it matters: it is often the earliest stage where intervention is possible. See [MCI and early detection](/topics/mild-cognitive-impairment-and-early-detection).

**Biomarker** is any measurable biological signal, whether in spinal fluid, on a PET scan, or increasingly in [blood](/topics/blood-based-biomarkers-alzheimers), that reflects what a disease process is doing.

## The heart and metabolic words

**LDL-C** is the cholesterol carried inside LDL particles, the “bad cholesterol” line on a standard panel.

**ApoB** is a protein riding on every artery-clogging particle, exactly one per particle. So measuring ApoB *counts* those particles directly, no matter how much cholesterol each one happens to carry. Why it matters: that makes it a sharper risk signal than LDL-C, and many carriers should track it. See [ApoB vs. LDL-C](/topics/apob-vs-ldl-cholesterol).

**Lp(a)** (“L-P-little-a”) is an LDL-like particle with an extra protein stuck to it that makes it both pro-inflammatory and prone to clotting. Levels are roughly 90% set by your genes and add cardiovascular risk on top of LDL. Why it matters: it is worth checking at least once in your life (above about 50 mg/dL, or 125 nmol/L, counts as elevated), because you cannot guess it from a normal cholesterol panel. See [lipoprotein(a) and APOE4](/topics/lipoprotein-a-and-apoe4).

**Insulin resistance** is when your cells stop responding well to insulin, the engine behind prediabetes. Why it matters: it is a real factor in both [metabolic and brain health](/topics/metabolic-health-insulin-resistance-apoe4).

**VO2max** is the maximum rate at which your body can use oxygen during hard exercise, and one of the single strongest predictors of long-term mortality (low fitness carries risk on par with major disease). Why it matters: it is highly trainable, which makes it one of your most powerful levers. See [Zone 2 and VO2max](/topics/zone-2-vo2max-and-cardio).

## The treatment and testing words

**Anti-amyloid antibodies** are drugs (such as lecanemab and donanemab) that clear amyloid from the brain and modestly slow early Alzheimer’s. See [the deep dive](/topics/anti-amyloid-drugs-and-apoe4).

**ARIA (amyloid-related imaging abnormalities)** is brain swelling (**ARIA-E**) or small bleeds (**ARIA-H**) that show up on MRI during anti-amyloid treatment. It is usually symptom-free but occasionally serious, and the risk depends heavily on genotype: in the lecanemab trial, ARIA-E occurred in roughly 5% of non-carriers, about 11% of ε3/ε4 heterozygotes, and around 33% of ε4/ε4 homozygotes. Why it matters: that gradient is exactly why your genotype now factors into treatment decisions. See [anti-amyloid drugs and APOE4](/topics/anti-amyloid-drugs-and-apoe4).

**GINA** is the U.S. Genetic Information Nondiscrimination Act. It protects your genetic information in health insurance and employment, but **not** in life, disability, or long-term-care insurance. Why it matters: this is the one practical thing to understand before you test. See [how to get tested](/topics/how-to-get-tested-for-apoe4).

**Genetic counselor** is a trained professional who helps you understand genetic results and decide about testing on your own terms. Why it matters: a good one turns a scary raw result into a plan.

* * *

If a term you have hit is not here, it is a fair bet it links back to one of the [deep dives](/topics). If you spot something we should add, that is exactly the kind of gap we want to close.

## Sources & further reading

1.  [National Institute on Aging: What Happens to the Brain in Alzheimer’s Disease](https://www.nia.nih.gov/health/alzheimers-causes-and-risk-factors/what-happens-brain-alzheimers-disease)
2.  [MedlinePlus Genetics: APOE gene](https://medlineplus.gov/genetics/gene/apoe/)
3.  [Alzheimer’s Association: Lecanemab (Leqembi)](https://www.alz.org/alzheimers-dementia/treatments/lecanemab-leqembi)
4.  [van Dyck et al. (2023), NEJM (CLARITY-AD): Lecanemab in early Alzheimer disease](https://www.nejm.org/doi/full/10.1056/NEJMoa2212948)
5.  [Fortea et al. (2024), Nature Medicine: APOE4 homozygosity as a distinct genetic form of Alzheimer disease](https://www.nature.com/articles/s41591-024-02931-w)

## Related deep dives

-   [What is APOE4? A plain-language primer APOE4 is the most common genetic risk factor for late-onset Alzheimer’s. What the gene does, what carrying one or two copies means, and the crucial things it does not mean.](/topics/what-is-apoe4)
-   [The APOE genotypes explained: from 2/2 to 4/4 You inherit one APOE allele from each parent. What each of the six pairs, from protective 2/2 to higher-risk 4/4, actually means for risk, in plain numbers.](/topics/apoe4-genotypes-explained)
-   [APOE4 myths vs. facts Carrier forums and headlines spread a lot of half-truths about APOE4. The recurring ones worth correcting, and what the evidence actually supports.](/topics/apoe4-myths-vs-facts)
-   [Should you get tested for APOE4, and how? A decision-first guide to APOE4 testing: when knowing may help, when it may not, and how clinical and consumer routes differ in accuracy, privacy, and support.](/topics/how-to-get-tested-for-apoe4)